Marex Group’s Definium Therapeutics DFTX Stock Holding History

Marex Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$378K	Hold	20,000	–	–	﹤0.01%	701
2025 Q4	$268K	Buy	+20,000	New	+$248K	﹤0.01%	738

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marex Group's DFTX Position: Q1 2026 in Review

Marex Group held its Definium Therapeutics (DFTX) position steady in Q1 2026 at 20,000 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Marex Group first reported a position in DFTX in Q4 2025 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Marex Group held 20,000 shares of Definium Therapeutics worth $378K as of Q1 2026.
Marex Group left its Definium Therapeutics share count unchanged in Q1 2026.
Definium Therapeutics made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #701 holding.
Marex Group first reported a position in Definium Therapeutics in Q4 2025 and has held it in 2 quarters since.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.